Segment Information (Tables)

6 Months Ended

Jun. 30, 2012

Segment Reporting Information, Revenue for Reportable Segment [Abstract]

Schedule Of Financial Data For Two Business Segments

	Three months ended						Six months ended
	June 30, 2012			June 30, 2011			June 30, 2012			June 30, 2011
Revenues:
Par Pharmaceutical	$	273,109		$	202,449		$	524,276		$	412,193
Strativa	21,224			21,739			41,529			44,947
Total revenues	$	294,333		$	224,188		$	565,805		$	457,140
Gross margin:
Par Pharmaceutical	$	127,121		$	83,994		$	209,571		$	176,554
Strativa	16,033			15,032			31,429			32,125
Total gross margin	$	143,154		$	99,026		$	241,000		$	208,679
Operating income (loss):
Par Pharmaceutical	$	81,408		$	51,845		$	105,456		$	(80,901	)
Strativa	1,363			(34,038		)	(43,898		)	(39,854		)
Total operating income (loss)	$	82,771		$	17,807		$	61,558		$	(120,755	)
Interest income	140			382			276			805
Interest expense	(3,069		)	(150		)	(6,163		)	(301		)
Provision (benefit) for income taxes	28,537			8,859			33,062			(20,587		)
Income (loss) from continuing operations	$	51,305		$	9,180		$	22,609		$	(99,664	)

Schedule Of Total Revenues Of Top Selling Products

Product	Three months ended				Six months ended
	June 30, 2012		June 30, 2011		June 30, 2012		June 30, 2011
Par Pharmaceutical
Modafinil (Provigil®)	$	57,484	$	—	$	57,484	$	—
Metoprolol succinate ER (Toprol-XL®)	48,953		63,706		110,718		127,124
Budesonide (Entocort® EC)	33,513		16,357		71,497		16,357
Propafenone (Rythmol SR®)	17,888		13,311		36,980		35,350
Sumatriptan succinate injection (Imitrex®)	13,945		15,284		30,644		31,983
Bupropion ER (Wellbutrin®)	12,010		—		23,364		—
Chlorpheniramine/Hydrocodone (Tussionex®)	7,984		7,022		21,941		19,701
Zolpidem (Ambien CR®)	5,342		—		12,264		—
Cholestyramine Powder (Questran®)	4,958		4,077		9,878		7,760
Tramadol ER (Ultracet ER®)	4,593		5,873		10,422		11,954
Dronabinol (Marinol®)	4,444		8,118		12,047		14,989
Meclizine Hydrochloride (Antivert®)	3,783		4,562		7,969		9,437
Amlodipine and Benazepril HCl (Lotrel®)	1,729		12,505		4,177		30,675
Nateglinide (Starlix®)	3,518		3,815		7,542		8,120
Other (1)	46,170		38,774		95,160		81,809
Other product related revenues (2)	6,795		9,045		12,189		16,934
Total Par Pharmaceutical Revenues	$	273,109	$	202,449	$	524,276	$	412,193

Product	Three months ended					Six months ended
	June 30, 2012			June 30, 2011		June 30, 2012			June 30, 2011
Strativa
Megace® ES	$	14,212		$	14,050	$	26,390		$	28,135
Nascobal® Nasal Spray	5,380			6,274		11,312			10,152
Oravig®	(3		)	1,027		152			1,776
Zuplenz®	(106		)	263		(21		)	485
Other product related revenues (2)	1,741			125		3,696			4,399
Total Strativa Revenues	$	21,224		$	21,739	$	41,529		$	44,947

(1) No single product in the other category is in excess of 3% of total generic revenues for the six-month period ended June 30, 2012 or for the six-month period ended June 30, 2011.

(2) Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as diazepam rectal gel, the generic version of Diastat®, and fenofibrate, the generic version of Tricor®.  Other product related revenues included in the Strativa segment relate primarily to Strativa’s share of the proceeds from Optimer Pharmaceuticals’ sale of certain rights in fidaxomicin to a third party.